An intro month, and then a range
The weight-loss page prices each lane in two parts: an intro month and the months after it. For the injection, the second figure is a span rather than a number, and the page says why — the dose the provider recommends decides it. For the oral preparation, the second figure is a floor with a plus sign after it, which sets a bottom and no top at all.
That is more honest than publishing only the intro figure, which is what much of this market does. It is also less useful than it looks. A patient cannot work out a year from a range whose upper end is unstated, and the oral lane's ongoing figure has no upper end at all.
We have stored the intro month for each lane as the price, with the ongoing figures written into the qualifier, because that is the only number on the page that is a number.
The entity, and the clinical group behind it
The terms page opens by naming the company that owns and operates this domain, and gives a postal address for it three times on the same page. A separate sentence names the professional provider group the clinical service runs under. Two names, both tied to this site, both readable without an intake.
That is worth saying plainly because it is unusual. Many sellers in this category publish legal pages that name a platform vendor, a payment processor and an arbitration administrator, and never name themselves.
The arbitration clause names a different administrator and a different state from the boilerplate that recurs across this market, which is a small sign that the document was drafted rather than copied.
The comparison it draws with everyone else
The same page sets its own figures against a band of hidden platform fees it attributes to unnamed other providers. That band is the seller's own characterisation of its competitors, not a measurement of them, and nothing on the page says where it came from.
We have not carried it into any figure here, and a reader should not either. A price a seller quotes for its rivals tells you what the seller wants you to believe about them.
The site also names an FDA-approved product on the same page as its compounded lanes. Read the checkout carefully: a brand name used to describe an ingredient is not the same as a brand-name product being sold.
Thrivelab's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $175/mointro month; the same block prints "Following Months $175-250 Based on provider recommendation dosage", so the ongoing figure is a dose-set range and not a rate | September 2026source |
| Semaglutide (compounded-oral) | $225/mointro month for the oral preparation; the following months are printed as "$300+", an open-ended floor rather than a figure | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 198 providers reviewed here are paid partners today; the other 194 are not. See how this works.
See Thrivelab's current price →Good fit if
- Readers who want an injectable and an oral compounded semaglutide priced by the same seller, on the same page.
- Buyers who would rather see an imperfect second-month figure than none at all.
- People who want the operating company and the clinical group named before they start an intake.
- Anyone comparing what an intro rate buys against what the months after it cost.
Look elsewhere if
- Readers who need a fixed ongoing price. Neither lane publishes one.
- Anyone who wants the compounding pharmacy named; this site does not name one.
- Buyers who need to know whether their state is served before starting, since no service area is published.
- Readers for whom an FDA warning letter is disqualifying.
How this review was verified
- Re-read the priced weight-loss page and the terms page on 7 September 2026, comparing the requested path to the effective path on each and running a nonsense path against the host in the same run, which returned a 404.
- Joined text nodes before matching any price, so a currency symbol and a figure sitting in separate elements read as one number rather than two.
- Read the entity sentence in full rather than accepting a pattern match, and confirmed the pattern that found it by first running it against a page we knew names a company.
- Screened the entity and the brand against FDA's live warning-letter datatable with a known letter as a positive control and a nonsense string as a negative control in the same invocation, then re-fetched the letter itself and confirmed its title matches the entity, the reference number and the issue date. A minted nonsense letter path on the same host returned a 404 in the same run.
- Recorded the competitor-fee band as the seller's own claim and excluded it from every stored figure.